Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation - Marquardt, Viktoria; Theruvath, Johanna; Pauck, David; Picard, Daniel; Qin, Nan; Blümel, Lena; Maue, Mara; Bartl, Jasmin; Ahmadov, Ulvi; Langini, Maike; Meyer, Frauke-Dorothee; Cole, Allison; et al. (Journal for ImmunoTherapy of Cancer, 2023)
Online veröffentlicht: 13. Januar 2023